More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Subscribe To Our Newsletter & Stay Updated
